Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03504800 · ClinicalTrials.gov registry record
OCT in Diagnosis of Irregular Corneas
A clinical trial of Keratoconus and Corneal Opacity, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- 445
- Enrollment target
- 1
- Study location
NCT03504800: Recruiting study of Keratoconus and Corneal Opacity, sponsored by Oregon Health and Science University.
NCT03504800 is a study of Keratoconus and Corneal Opacity that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 445 participants, below the 1,159-participant average among 21 other Keratoconus trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03504800, a study of Keratoconus and Corneal Opacity, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- 445 participants
- Enrollment target
- 1
- Study location
Study Summary
This main goal of this study is to improve the detection, classification, monitoring, and treatment of irregular corneas due to keratoconus, warpage, dry eye, scar, stromal dystrophies, and other corneal conditions. The primary goal will be achieved by using optical coherence tomography (OCT) to: 1. Develop an OCT-based system to classify and evaluate corneal-shape irregularities. 2. Develop OCT metrics for more sensitive detection of keratoconus progression. 3. Develop OCT-and-topography guided phototherapeutic keratectomy (PTK) for irregular corneas.
Primary Outcome
Clinical classification of keratoconus, epithelial deformation, stromal addition/subtraction, stromal distortion, and healthy controls by OCT. Primary measurements will be corneal and epithelial thicknesses assessed in micron units.
Conditions Studied
Interventions
- DEVICE Optical Coherence Tomography
Study Locations (1)
Oregon
- Humberto Martinez - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 445 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2031-02-28 |
What NCT03504800 shows while recruiting
NCT03504800 is an observational study that tracks outcomes without assigning an intervention. The registered 445 participants enrollment target is mid-sized for trials with a published cap, below the 1,159-participant average among 21 other Keratoconus trials with a reported enrollment target (62% lower).
The record links to 3 conditions, with Keratoconus appearing as the primary indexed condition, and to 1 intervention - of which Optical Coherence Tomography is the first listed.
NCT03504800 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT03504800 about?
NCT03504800 is a clinical study titled "OCT in Diagnosis of Irregular Corneas". This main goal of this study is to improve the detection, classification, monitoring, and treatment of irregular corneas due to keratoconus, warpage, dry eye, scar, stromal dystrophies, and other corneal conditions. The primary goal will be achieved by using optical coherence tomography (OCT) to: ...
What is the current status of trial NCT03504800?
This trial is currently recruiting. The enrollment target is 445 participants. The study started on 2018-05-01. Estimated completion is 2031-02-28.
What conditions does trial NCT03504800 study?
This clinical trial studies the following conditions: Keratoconus, Corneal Opacity, Corneal Dystrophy.
What interventions are being tested in trial NCT03504800?
The interventions under investigation include: Optical Coherence Tomography (DEVICE).
Who is sponsoring clinical trial NCT03504800?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03504800 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Keratoconus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03504800's enrollment target sits among peer trials
445 5th of 21 higher than 17 of 21 other Keratoconus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Keratoconus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
RECRUITING
-
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
RECRUITING · Phase 3
-
Collagen Cross-linking in Keratoconus
RECRUITING · NA
-
Corneal Elastography and Patient Specific Modeling
RECRUITING
-
Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome
RECRUITING · Phase 3
-
Safety and Effectiveness of the PXL-Platinum 330 System for Cornea Crosslinking in Eyes With Cornea Thinning
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT04751435 · 445 participants · NA
Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI